Molecular Pharmacology Program

The Neal Rosen Lab

Share
Print

Research

Pictured: Neal Rosen
Neal Rosen, MD, PhD


Professor

The main goal of our laboratory is the identification and characterization of signal transduction pathways that cause the dysregulation of growth and inhibition of apoptosis that characterize advanced human cancer. Our laboratory is dedicated to understanding the consequences of activation of these pathways and to using this information to develop mechanism-based therapeutic strategies.

View Lab Overview

Research Projects

Neal Rosen Lab Group

Publications

Yao, Z., Gao, Y., Su, W., Yaeger, R., Tao, J., Na, N., Zhang, Y., Zhang, C., Rymar, A., Tao, A., Timaul, N. M., Mcgriskin, R., Outmezguine, N. A., Zhao, H., Chang, Q., Qeriqi, B., Barbacid, M., de Stanchina, E., Hyman, D. M., Bollag, G., … Rosen, N. (2019). RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nature medicine, 25(2), 284–291. https://doi.org/10.1038/s41591-018-0274-5

Gao, Y., Chang, M. T., McKay, D., Na, N., Zhou, B., Yaeger, R., Torres, N. M., Muniz, K., Drosten, M., Barbacid, M., Caponigro, G., Stuart, D., Moebitz, H., Solit, D. B., Abdel-Wahab, O., Taylor, B. S., Yao, Z., & Rosen, N. (2018). Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer discovery, 8(5), 648–661. https://doi.org/10.1158/2159-8290.CD-17-1452

Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., Jayakumaran, G., Middha, S., Zehir, A., Donoghue, M., You, D., Viale, A., Kemeny, N., Segal, N. H., Stadler, Z. K., Varghese, A. M., Kundra, R., Gao, J., Syed, A., Hyman, D. M., … Schultz, N. (2018). Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer cell, 33(1), 125–136.e3. https://doi.org/10.1016/j.ccell.2017.12.004

Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., Baselga, J., de Stanchina, E., Saltz, L., Berger, M. F., Solit, D. B., & Rosen, N. (2017). Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer research, 77(23), 6513–6523. https://doi.org/10.1158/0008-5472.CAN-17-0768

Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., Michels, J., Baumert, H., Miles, L., Campbell, N. M., de Stanchina, E., Solit, D. B., Barbacid, M., Taylor, B. S., & Rosen, N. (2017). Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature, 548(7666), 234–238. https://doi.org/10.1038/nature23291.

View All Publications

People

Pictured: Neal Rosen

Neal Rosen, MD, PhD



Professor

  • Pharmacologist Neal Rosen focuses on understanding biochemical mechanisms underlying phenotypes caused by tyrosine kinase activation in epithelial tumors and developing new therapeutic strategies.
  • MD, PhD, Albert Einstein College of Medicine
rosenn@mskcc.org
Email Address
646-888-2075
Office Phone
View physician profile
Physician profile

Members

Yu Bian

Research Technician

Jacob A. Boyer, BS
Jacob A. Boyer

Graduate Student

Sunyana Gadal
Sunyana Gadal

Research Fellow

Yijun Gao
Yijun Gao

Research Associate

Alessandria Greco

Research Technician

Hidenori Kitai
Hidenori Kitai

Visiting Investigator

Michelangelo Marasco

Research Fellow

Rory Mcgriskin
Rory Mcgriskin

Medical Lab Assistant

Sandra Misale
Sandra Misale

Research Associate

Radha Mukherjee
Radha Mukherjee

Research Fellow

Jason Reiter

Research Technician

Malvika Sharma

Research Fellow

Hilla Solomon
Hilla Solomon

Research Associate

Wenjing Su
Wenjing Su

Research Associate

Claire Thant
Claire Thant

Senior Research Technician

N. Merna Timaul
N. Merna Timaul

Lab Manager

Adele Whaley
Adele Whaley

Graduate Student

Rona Yaeger
Rona Yaeger

Assistant Attending Physician, Department of Medicine

Lab Alumni
Liqun Cai

Former Research Technician

Sarat Chandarlapaty

Assistant Member, Human Oncology and Pathogenesis Program; Department of Medicine, Memorial Sloan Kettering Cancer Center

Poulikos Poulikakos

Assistant Professor, Mount Sinai

Andreja Jovic

Research Fellow

Qing-Bai She

Faculty, University of Kentucky

Piro Lito
Piro Lito

Medical Oncology Fellow

David Solit

Director, Developmental Therapeutics; Associate Professor of Medicine; Cell and Developmental Biology, Memorial Sloan Kettering Cancer Center

Oren Litvin

Former Graduate Student

Christine A. Pratilas

Assistant Attending, Department of Pediatrics

Sarit Schwartz

Research Fellow

Martha Solomon

Research Technician

Sharmeen Uddin

Former Research Technician

Marie Will

Former Graduate Student

Paige Yellen

Research Fellow

Jingyin Yue

Former Research Fellow

Arpitha Banaji

Research Technician

Laura Desrochers

Research Fellow

Keven Muniz

Lab Technician

Na Na
Na Na

Research Technician

Virginia Ojeda Seijas
Virginia Ojeda Seijas

Research Fellow

Vanessa Rodrik-Outmezguine
Vanessa Rodrik-Outmezguine

Senior Scientist

Alberto Vides

Research Technician

Jianing Xu
Jianing Xu

Research Associate

Zhan Yao
Zhan Yao

Assistant Lab member

Lab Affiliations

Open Positions

Postdoctoral Positions

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Neal Rosen discloses the following relationships and financial interests:

  • BeiGene, Ltd.
    Ownership / Equity Interests
  • Concarlo Holdings, LLC
    Provision of Services
  • Fortress Biotech Inc
    Ownership / Equity Interests
  • Jubilant Therapeutics Inc.
    Provision of Services
  • Kura Oncology
    Ownership / Equity Interests
  • Lutris Pharma Ltd.
    Intellectual Property Rights
  • MapKure LLC
    Ownership / Equity Interests; Provision of Services
  • Novartis Institutes for BioMedical Research, Inc.
    Provision of Services
  • Ribon Therapeutics
    Ownership / Equity Interests; Provision of Services
  • Samus Therapeutics LLC
    Intellectual Property Rights
  • Sanofi US Services Inc.
    Provision of Services
  • Tarveda Therapeutics, Inc
    Provision of Services
  • Verastem
    Provision of Services (uncompensated)
  • Zai Lab
    Ownership / Equity Interests; Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures